Form 4 for RMD ResMed|
Accepted 2026-04-03 07:29:26 ET · period of report 2026-04-01 · accession 0000943819-26-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-04-03 07:29 | 2026-04-01 | RMD | Sandercock Brett | CFO | S - Sale | $224.31 | -1,000 | 83.5K | -1% | -$224.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2026-04-01 | S | D | 1,000 | $224.31 | 83,495 | D | — | — | (F1) The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. |